ONC
ONC clinical trials: BeOne Medicines Ltd.
Every trial on ClinicalTrials.gov where BeOne Medicines Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 289
- Trials linked
- 195
- As lead sponsor
- 94
- As collaborator
- 6
- Primary completions as lead sponsor, next 90 days
ONC on the catalyst calendar · ONC registry changes
- Primary completion Feb 27, 2029Sponsor estimatePhase 1NCT07904845A Study of BON-C1393 in Adults With Advanced Solid TumorsBeOne Medicines · Solid TumorsNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2029Sponsor estimatePhase 1NCT07222267An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsBeOne Medicines · Breast CancerRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 15, 2028Sponsor estimatePhase 3NCT06846671A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small...BeOne Medicines · CLLRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 11, 2027Sponsor estimatePhase 1NCT07934069A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of BON-107 in Healthy ParticipantsBeOne Medicines · Healthy ParticipantsNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 21, 2029Sponsor estimatePhase 3NCT07836530Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular CarcinomaBeOne Medicines · Hepatocellular CarcinomaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2027Sponsor estimatePhase 1NCT07856004A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe...BeOne Medicines · Hepatic ImpairmentNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2025ActualPhase 2NCT05635708A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerBeiGene · Non-small Cell Lung CancerCompletedONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2028Sponsor estimatePhase 2NCT07911683Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular CarcinomaBeOne Medicines · Hepatocellular CancerNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2028Sponsor estimatePhase 3NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With...BeOne Medicines · Mantle Cell LymphomaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2028Sponsor estimatePhase 1NCT06596473A Study of BG-C477 in Participants With Advanced Solid TumorsBeOne Medicines · Advanced Solid TumorsRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 28, 2028Sponsor estimatePhase 2NCT07733180A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCBeOne Medicines · Advanced Esophageal Squamous Cell CarcinomaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2029Sponsor estimatePhase 3NCT07492641BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not...BeOne Medicines · HR+/HER2- Breast CancerRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2029Sponsor estimatePhase 1/Phase 2NCT06697184A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.BeOne Medicines · Chronic Lymphocytic LeukemiaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 1/Phase 2NCT04973605A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib...BeOne Medicines · Relapsed/Refractory Multiple MyelomaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 2NCT03736889Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsBeiGene · MSI-H/dMMR Solid TumorsRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2030Sponsor estimatePhase 1/Phase 2NCT07770698A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaBeOne Medicines · Relapsed Acute Myeloid LeukemiaNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 26, 2026ActualPhase 1NCT07628881A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsBeOne Medicines · Healthy VolunteersCompletedONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 29, 2028Sponsor estimatePhase 1NCT07896460A First-in-Human Study of BG-92505 Alone or in Combination With Other Anti-cancer Agents in Patients With Advanced Solid TumorsBeOne Medicines · Advanced Solid TumorNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2026Sponsor estimatePhase 1NCT07820891A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395BeOne Medicines · Healthy Adult ParticipantsRecruitingONCLeadFTRECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2028Sponsor estimatePhase 1NCT07746141A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or...BeOne Medicines · RAS MutationRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2029Sponsor estimatePhase 3NCT06943872A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With...BeOne Medicines · Chronic Lymphocytic LeukemiaRecruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimatePhase 1NCT07893535An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid TumorsBeOne Medicines · Solid TumorNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2027Sponsor estimatePhase 1NCT07855991A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic ImpairmentBeOne Medicines · Hepatic ImpairmentNot yet recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 27, 2026ActualPhase 1NCT06257264A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsBeiGene · Breast CancerActive, not recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2026ActualPhase 2NCT05952037A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults...BeOne Medicines · Waldenstrom MacroglobulinemiaActive, not recruitingONCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 264 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner